IN8bio Inc

IN8bio operates with a market capitalization of $15.66 million and a price-to-book ratio of 1.15, indicating that the market values the company slightly above its book value. The company's liquidity position is characterized by a current ratio of 2.66, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -$14.01 million, and its free cash flow is also negative at -$8.29 million, indicating a lack of cash generation from operations. Profitability metrics show that IN8bio is currently unprofitable, with a net income of -$8.63 million and an operating income of -$8.69 million. The company's return on equity is -63.35%, and its return on assets is -38.36%, both of which are significantly below the industry median for biotechnology firms. The debt-to-equity ratio is 0.1, indicating a relatively low level of leverage compared to industry peers. IN8bio's revenue is not disclosed in the provided data, and the company does not report segment or geographic revenue breakdowns. As a pre-revenue biotechnology firm, the company's operations are likely concentrated in research and development, with no significant geographic diversification. The absence of revenue concentration data suggests that the company is in an early stage of development and has not yet commercialized its products. The company's growth trajectory is uncertain, as it has not yet achieved profitability and is experiencing negative cash flows. The outlook for the current fiscal year is not provided, but the company's operating performance suggests a challenging path to growth. The absence of revenue history and the lack of positive cash flow metrics indicate that the company is in a high-risk, high-revenue-growth phase. Risk factors for IN8bio include its negative net cash position after subtracting total debt, which raises concerns about its ability to fund operations without additional financing. The company's liquidity risk is rated as medium, and while dilution risk is currently low, the need for further capital could increase the risk of equity dilution in the future. The company has not disclosed any recent events such as filings or transcripts that would provide additional insight into its operations or strategic direction. Recent investor sentiment, as reflected in analyst estimates, is cautiously optimistic. The mean price target is $6.25, with a median of $5.50, and the highest price target is $10.00. The mean recommendation is 2.00, indicating a "Buy" rating, with four analysts issuing a "Buy" recommendation and none issuing a "Strong Buy".